LENZ Therapeutics Stock (NASDAQ:LENZ)
Previous Close
$27.72
52W Range
$16.54 - $50.40
50D Avg
$35.89
200D Avg
$30.95
Market Cap
$794.06M
Avg Vol (3M)
$932.79K
Beta
0.45
Div Yield
$7.21
LENZ Company Profile
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.